Abiopharma

Neural Therapeutics is an ethnobotanical drug discovery company, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand Hanf.com, to acquire up to 100% of CWE through a multi-stage transaction. On August 13, 2025, Neural completed the first stage of this transaction, acquiring a 30.75% equity interest in CWE. The investment provides Neural with exposure to Hanf.coms established retail and eCommerce operations, which include 15 stores in Germany (11 directly owned and 4 franchises) and a growing product portfolio. The transaction is expected to expand Neurals commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation.

Additional info from OTC:
Neural Therapeutics is an ethnobotanical drug discovery company, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand Hanf.com, to acquire up to 100% of CWE through a multi-stage transaction. On August 13, 2025, Neural completed the first stage of this transaction, acquiring a 30.75% equity interest in CWE. The investment provides Neural with exposure to Hanf.coms established retail and eCommerce operations, which include 15 stores in Germany (11 directly owned and 4 franchises) and a growing product portfolio. The transaction is expected to expand Neurals commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation.